

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ACCORD BIOPHARMA, INC., INTAS PHARMACEUTICALS LTD., AND
BIO-THERA SOLUTIONS, LTD.,
Petitioner,

v.

JANSSEN BIOTECH, INC.,
Patent Owner.

IPR2026-00258
Patent No. 12,122,824

DECLARATION OF ANN DONLON

I, Ann Donlon, hereby declare as follows.

1. I am a Vice President of Value Chain Management at Janssen Ireland Sourcing, which is part of the Johnson & Johnson (J&J) family of companies, and I have personal knowledge of the facts set forth in this declaration. If called as a witness, I could and would testify competently thereto.

2. [REDACTED]

[REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED] [REDACTED]

[REDACTED]

3. In the first quarter of 2026, J&J announced a new, state-of-the-art, 500,000 square foot biologics Drug Product manufacturing facility in Wilson, North Carolina (the “Wilson facility”).

4. The Wilson facility represents an investment of more than \$2 billion in U.S. manufacturing capacity for biologic products by J&J on behalf of Janssen Biotech, Inc. (“Janssen”). J&J is the parent company of Janssen. Once fully operational, the Wilson facility will employ more than 500 specialized employees.

5. The Wilson facility is part of J&J’s broader plan to invest more than \$55 billion in U.S. research and development, technology, and manufacturing over

the next four years. [REDACTED]

[REDACTED]

6. [REDACTED]

[REDACTED] [REDACTED] [REDACTED]

[REDACTED]

[REDACTED] [REDACTED] [REDACTED]

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Executed on Ann Donlon, 2026, at 26 May '26.